In breast cancer cells, AdoMet reduces cell viability and induces apoptosis by activating authophagy in MCF-7 cells [30] and by enhancing Fas/FasL in CG5 cells [31] and attenuates proliferation, invasion, and metastasis in vivo in the MDA-MB-231 xenograft model [32]. This evidence concerns the gene FAS and breast cancer.